肝细胞癌的免疫疗法:免疫检查点抑制剂、耐药性和不良反应概述

IF 1.4 4区 医学 Q4 ONCOLOGY
Xuan-Yu Gu, Jin-Long Huo, Zhi-Yong Yu, Ji-Chang Jiang, Ya-Xuan Xu, Lijin Zhao
{"title":"肝细胞癌的免疫疗法:免疫检查点抑制剂、耐药性和不良反应概述","authors":"Xuan-Yu Gu, Jin-Long Huo, Zhi-Yong Yu, Ji-Chang Jiang, Ya-Xuan Xu, Lijin Zhao","doi":"10.1515/oncologie-2023-0412","DOIUrl":null,"url":null,"abstract":"Abstract Hepatocellular carcinoma (HCC) is a concerning liver cancer with rising incidence and mortality rates worldwide. The effectiveness of traditional therapies in managing advanced HCC is limited, necessitating the development of new therapeutic strategies. Immune checkpoint inhibitors (ICIs) have emerged as a promising strategy for HCC management. By preventing tumor cells from evading immune surveillance through immunological checkpoints, ICIs can restore the immune system’s ability to target and eliminate tumors. While ICIs show promise in enhancing the immune response against malignancies, challenges such as drug resistance and adverse reactions hinder their efficacy. To address these challenges, developing individualized ICI treatment strategies is critical. Combining targeted therapy and immunotherapy holds the potential for comprehensive therapeutic effects. Additionally, biomarker-based individualized ICI treatment strategies offer promise in predicting treatment response and guiding personalized patient care. Future research should explore emerging ICI treatment methods to optimize HCC immunotherapy. This review provides an overview of ICIs as a new treatment for HCC, demonstrating some success in promoting the tumor immune response. However, drug resistance and adverse reactions remain important considerations that must be addressed. As tailored treatment plans evolve, the prospect of immunotherapy for HCC is expected to grow, offering new opportunities for improved patient outcomes.","PeriodicalId":54687,"journal":{"name":"Oncologie","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2024-01-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects\",\"authors\":\"Xuan-Yu Gu, Jin-Long Huo, Zhi-Yong Yu, Ji-Chang Jiang, Ya-Xuan Xu, Lijin Zhao\",\"doi\":\"10.1515/oncologie-2023-0412\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract Hepatocellular carcinoma (HCC) is a concerning liver cancer with rising incidence and mortality rates worldwide. The effectiveness of traditional therapies in managing advanced HCC is limited, necessitating the development of new therapeutic strategies. Immune checkpoint inhibitors (ICIs) have emerged as a promising strategy for HCC management. By preventing tumor cells from evading immune surveillance through immunological checkpoints, ICIs can restore the immune system’s ability to target and eliminate tumors. While ICIs show promise in enhancing the immune response against malignancies, challenges such as drug resistance and adverse reactions hinder their efficacy. To address these challenges, developing individualized ICI treatment strategies is critical. Combining targeted therapy and immunotherapy holds the potential for comprehensive therapeutic effects. Additionally, biomarker-based individualized ICI treatment strategies offer promise in predicting treatment response and guiding personalized patient care. Future research should explore emerging ICI treatment methods to optimize HCC immunotherapy. This review provides an overview of ICIs as a new treatment for HCC, demonstrating some success in promoting the tumor immune response. However, drug resistance and adverse reactions remain important considerations that must be addressed. As tailored treatment plans evolve, the prospect of immunotherapy for HCC is expected to grow, offering new opportunities for improved patient outcomes.\",\"PeriodicalId\":54687,\"journal\":{\"name\":\"Oncologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2024-01-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1515/oncologie-2023-0412\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/oncologie-2023-0412","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

摘要 肝细胞癌(HCC)是一种令人担忧的肝癌,其发病率和死亡率在全球不断上升。传统疗法对晚期肝细胞癌的治疗效果有限,因此有必要开发新的治疗策略。免疫检查点抑制剂(ICIs)已成为一种很有前景的HCC治疗策略。通过免疫检查点阻止肿瘤细胞逃避免疫监视,ICIs 可以恢复免疫系统靶向和消灭肿瘤的能力。虽然 ICIs 有望增强针对恶性肿瘤的免疫反应,但耐药性和不良反应等挑战阻碍了 ICIs 的疗效。为了应对这些挑战,制定个体化的 ICI 治疗策略至关重要。将靶向治疗与免疫治疗相结合,有可能产生全面的治疗效果。此外,基于生物标志物的个体化 ICI 治疗策略有望预测治疗反应并指导个性化患者护理。未来的研究应探索新兴的 ICI 治疗方法,以优化 HCC 免疫疗法。本综述概述了 ICIs 作为 HCC 新疗法的情况,显示其在促进肿瘤免疫反应方面取得了一些成功。然而,耐药性和不良反应仍然是必须解决的重要问题。随着量身定制的治疗方案不断发展,HCC 免疫疗法的前景有望扩大,为改善患者预后提供了新的机遇。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Immunotherapy in hepatocellular carcinoma: an overview of immune checkpoint inhibitors, drug resistance, and adverse effects
Abstract Hepatocellular carcinoma (HCC) is a concerning liver cancer with rising incidence and mortality rates worldwide. The effectiveness of traditional therapies in managing advanced HCC is limited, necessitating the development of new therapeutic strategies. Immune checkpoint inhibitors (ICIs) have emerged as a promising strategy for HCC management. By preventing tumor cells from evading immune surveillance through immunological checkpoints, ICIs can restore the immune system’s ability to target and eliminate tumors. While ICIs show promise in enhancing the immune response against malignancies, challenges such as drug resistance and adverse reactions hinder their efficacy. To address these challenges, developing individualized ICI treatment strategies is critical. Combining targeted therapy and immunotherapy holds the potential for comprehensive therapeutic effects. Additionally, biomarker-based individualized ICI treatment strategies offer promise in predicting treatment response and guiding personalized patient care. Future research should explore emerging ICI treatment methods to optimize HCC immunotherapy. This review provides an overview of ICIs as a new treatment for HCC, demonstrating some success in promoting the tumor immune response. However, drug resistance and adverse reactions remain important considerations that must be addressed. As tailored treatment plans evolve, the prospect of immunotherapy for HCC is expected to grow, offering new opportunities for improved patient outcomes.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncologie
Oncologie 医学-肿瘤学
CiteScore
1.30
自引率
11.10%
发文量
32
审稿时长
6-12 weeks
期刊介绍: Oncologie is aimed to the publication of high quality original research articles, review papers, case report, etc. with an active interest in vivo or vitro study of cancer biology. Study relating to the pathology, diagnosis, and advanced treatment of all types of cancers, as well as research from any of the disciplines related to this field of interest. The journal has English and French bilingual publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信